DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-25 are pending. Claims 4, 7-9, 20-21 and 24-25 are rejected. Claims 1, 14 and 18 are objected to. Claims 2-3, 5-6, 10-13, 15-17, 19 and 22-23 are allowed.
Priority
This application is a CON of PCT/CN2023/139821 filed 12/19/2023. Acknowledgment is made of applicant's claim for foreign priority based on applications filed in China on 12/22/2022 and 07/18/2023. It is noted, however, that applicant has not filed a certified copy of the 202211654524.3 and 202310879936.5 applications as required by 37 CFR 1.55.
Information Disclosure Statement
The information disclosure statement(s) (IDS) dated 12/12/2024 has been considered.
Claim Objections
Claims 1, 4, 7, 9, 14, 18 and 20 are objected to because of the following informalities:
Claim 1 has a period that is not at the end of the claim. See page 1 line 16 and MPEP 608.01(m).
Claims 1, 7 and 18 have figure/scheme images with poor resolution. Applicant should exchange.
Claims 1, 4, 9, 14 and 20 are objected to for being written in improper Markush format.
Claim 1:
Page 1, line 9: delete “and”;
Page 1, line 14: delete first “and”;
Page 1, line 17: add “or” at the beginning of the line;
Page 1, line 19: delete “and”;
Page 1, line 25: delete first “and”;
Page 2, line 2: delete first “and”;
Page 2, line 6: delete first “and”;
Claim 9:
Line 18: add “and” before cesium;
Line 19: change “and” to “or”;
Line 21: add “and” before pyridine and change “and” to “or”;
Line 23: change “or” to “and”;
Line 25: add “and” before tetrahydrofuran and change “and” to “or”; and
Claim 14, line 23: add “and” before myeloma and change “and” to “or”.
See MPEP 2173.05(h).
Appropriate correction is required.
Claim Rejections - 35 USC § 112(a)
The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 24 and 25 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for inhibiting growth of lung cancer cells and colon cancer cell, does not reasonably provide enablement for treatment of “a tumor disease, a cardiovascular and cerebrovascular disease and a neurological disease” as outlined in claim 24 or even tumor diseases generally, as indicated in claim 25. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention as claimed. Accordingly, the method of claims 24-25 are not enabled.
Nature of the invention:
The invention is drawn to a method of treating a disease or disorder comprising administration of a compound of Formula (IV),
PNG
media_image1.png
170
204
media_image1.png
Greyscale
, as recited in instant claim 16.
Breadth of the invention:
The scope of the claimed invention is very broad, as it is drawn to administration of any of the numerous compounds encompassed by Formula (IV) as instantly recited to treat a tumor disease, a cardiovascular and cerebrovascular disease and a neurological disease.
State of the prior art and predictability in the art:
No compound has ever been found to treat a tumor disease, a cardiovascular and cerebrovascular disease and a neurological disease as recited in claim 24 generally, or even a tumor disease as recited in claim 25. Since this assertion is contrary to what is known in medicine, proof must be provided that this revolutionary assertion has merits. As it relates to cancer, for instance, the existence of such a “silver bullet” is contrary to our present understanding of oncology. The state of the art is not indicative of any pharmaceutical agents that are useful in the treatment of cancer generally. At Page 1004, Cecil Textbook of Medicine states that “each specific type has unique biologic and clinical features that must be appreciated for proper diagnosis, treatment and study”. Different types of cancers affect different organs and have different methods of growth and harm to the body. Also see In re Buting, 163 USPQ 689 (CCPA 1969), wherein ‘evidence involving a single compound and two types of cancer, was held insufficient to establish the utility of the claims directed to disparate types of cancers’. Thus, it is beyond the skill of oncologists today to get an agent to be effective against cancers or tumors generally.
A similar statement appears at In re Application of Hozumi et. al., 226 USPQ 353: “In spite of the vast expenditure of human and capital resources in recent years, no one drug has been found which is effective in treating all types of cancer. Cancer is not a simple disease, nor is it even a single disease, but a complex of a multitude of different entities, each behaving in a different way”. There are compounds that treat a modest range of cancers, but no one has ever been able to figure out how to get a compound to be effective against cancer generally, or even a majority of cancers.
The attempts to find compounds to prevent or treat various cancers/tumors arguably constitute the single most massive enterprise in all of pharmacology. This has not resulted in finding any treatment for tumors generally. This is because it is now understood that there is no “master switch” for cancers generally; cancers arise from a bewildering variety of differing mechanisms. Even the most broadly effective antitumor agents are only effective against a small fraction of the vast number of different cancers known. This is true in part because cancers arise from a wide variety of sources, primarily a wide variety of failures of the body’s cell growth regulatory mechanisms, but also such external factors such as viruses (an estimated at least 20% are of viral origin e.g. Human papillomavirus, EBV, Hepatitis B and C, HHV-8, HTLV-1 and other retroviruses, and quite possibly Merkel cell polyomavirus, and there is some evidence that CMV is a causative agent in glioblastoma), exposure to chemicals such as tobacco tars, excess alcohol consumption (which causes hepatic cirrhosis, an important cause of HCC), ionizing radiation, and unknown environmental factors.
Similarly, In re Novak, 134 USPQ 335, 337-338 says “unless one with ordinary skill in the art would accept those allegations as obviously valid and correct, it is proper for the examiner to ask for evidence which substantiates them.” There is no such evidence in this case for a compound that treats all types of cancer. Likewise, In re Cartright, 49 USPQ2d 1464, states: “Moreover, we have not been shown that one of ordinary skill would necessarily conclude from the information expressly disclosed by the written description that the active ingredient” does what the specification surmises that it does. That is exactly the case here. Moreover, even if Applicant’s assertion that cancer in general could be treated with these compounds were plausible -- which it is not --, that “plausible” would not suffice, as was stated in Rasmusson v. SmithKline Beecham Corp., 75 USPQ2d 1297, 1301: “If mere plausibility were the test for enablement under section 112, applicants could obtain patent rights to “inventions” consisting of little more than respectable guesses as to the likelihood of their success.
It is commonly known in the pharmaceutical arts that shape dictates function wherein drugs which have a shape complimentary to the protein target will bind and have an effect (this is often referred to simplistically as a “Lock and Key” model). Given the varied shape of protein targets in cancer, it is pure fantasy to speculate that a single drug with a single three-dimensional shape will bind all protein targets implicated in cancer therapy and have an effect in treating all forms of the disease. As such, at present the “silver bullet” drug therapy to treat all forms of cancer is elusive and such a therapy is not recognized in the art where the reality is that different forms of cancer require different drug therapies.
Regarding bufalin and its derivatives specifically, Qian in WO 2011/085641 A1 disclose a method for inhibiting A549 or Bcap-37 cell growth in both in vitro and in vivo models using a compound of Formula I
PNG
media_image2.png
280
283
media_image2.png
Greyscale
(see page 1, para. [005]). See Examples IX and X on pages 38-40.
There do not appear to be examples in the prior art of bufalin derivatives that are able to treat the variety of disorders outlined in claim 24, or even all tumor diseases.
Level of ordinary skill in the art:
An ordinary artisan in the area of drug development would have experience in synthesizing chemical compounds for particular activities. The synthesis of new drug candidates, while complex, is routine in the art. The process of finding new drugs that have in vitro activity against a particular biological target (i.e., receptor, enzyme, etc.) is well known. Additionally, while high throughput screening assays can be employed, developing a therapeutic method, as claimed, prior to synthesizing and testing compounds is generally not well-known or routine, given the complexity of certain biological systems.
The amount of direction provided and working examples:
Applicant demonstrates inhibitory activity of Iva, IVb, and IVc against A549, HCT116 and 95D cells in vitro, which perform more or less on par with doxorubicin as a control. See Example 9 beginning on page 43 and Table 5 on pages 44-45. Applicant also discloses in vivo results of comparable compound 1c in a colorectal cancer mouse model, which had excellent tumor inhibition, in a similar range as known 5-fluorouracil.
No examples have been provided that would enable the instantly disclosed compounds for treating the broad range of diseases and disorders listed in claim 24, or the tumor diseases listed in claim 25.
Quantity of experimentation needed to use the invention
The quantity of experimentation needed is undue experimentation. A person having ordinary skill in the art would need not only to identify and/or develop metrics to be able to investigate the efficacy of the disclosed compounds in the treatment of diseases and disorders broadly, but would also need to evaluate the disclosed compounds, with no assurance of success.
The Applicant has not sufficiently disclosed examples demonstrating the efficacy of the instantly claimed compounds in treating diseases and disorders broadly. The utility thereof would not have been readily recognized by a person having ordinary skill in the art at the time of filing, as distinct diseases and disorders have mutually exclusive etiologies. The examples disclosed in the application are not sufficient to overcome the unpredictability of treating diseases and disorders broadly.
A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.
Genentech Inc. V Novo Nordisk A/S (CAFC) 42 USPQ 2d 1001 states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”. Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person having ordinary skill in the art would have to engage in undue experimentation to determine the efficacy of disclosed compounds in treating diseases and disorders broadly, with no assurance of success.
Applicant may amend claim 24, for example, as follows: “A method for treating a lung or colorectal cancer…” and cancelling claim 25.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 4, 7-9, and 20-21 are rejected under 35 U.S.C. 112(b) being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claim 4 includes the image of the synthesis of compound 1a, which includes structures 1, 2, 3, and reagents/solvents for performing the reactions:
PNG
media_image3.png
324
587
media_image3.png
Greyscale
. This synthesis is not embraced by the limitation of Formula 1a to 1l as recited in the claim. Accordingly, the metes and bounds of the claim are unclear. Applicant may amend the claim by, for instance, deleting the cited image and amending the statement “Formulas 1a to 1l” to “Formulas 1a and 1c to 1l”.
Claim 7 recites a synthetic route for preparing a bufalin derivative represented by Formula I, including structures with variables A, R1, R2, R3, R4, R5, R6 and R7. However, said variables are not defined in the claim. There is insufficient antecedent basis for these limitations. Dependent claims 8-9 are rejected as indefinite for the same reason since they do not correct the indefiniteness issue of their parent claims.
Claim 20 uses the language “comprising”, “containing” “includes”, or “including”, which are open-ended transition phrases. See page 9 lines 13, 23 and 28; page 10 lines 2, 12, 15, 20, and 23; page 11 lines 1, 9, 16, 18 and 27; page 12 lines 2, 4, 7, 9, 11, 14, 22, 26 and 29. Per MPEP 2111.03 I, the use of such language "does not exclude additional, unrecited elements of method steps." Accordingly, the metes and bounds of the claims cannot be sufficiently interpreted by a person having ordinary skill in the art.
Applicant may amend the claim to distinctly claim the subject matter which the inventor regards as the invention. It is suggested that Applicant amend the claim to delete each of the cited terms and the subject matter that follows. For instance, the first paragraph of claim 20 may be amended to: “The bufalin phosphate derivative according to claim 16, wherein the alkyl group is a monovalent saturated linear or branched alkyl group consisting of one to twelve carbon atoms
Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. Process Control Corp. v. HydReclaim Corp., 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999).
The term “alkyl” in claim 20 is used by the claim to mean something akin to “non-aromatic hydrocarbon groups,” while the accepted meaning is “saturated linear or branched alkyl chains.” The term is indefinite because by Applicant’s own definition, “alkyl” refers to saturated linear or branched alkyl chains, which does not include rings since they require at least one degree of unsaturation. See page 9, lines 12-15. Likewise, the term “alkenyl” in claim 20 includes cyclic examples, which should not be included given Applicant’s definition of the alkenyl as “a straight-chain or branched monovalent hydrocarbon radical…”. See page 9, lines 22-23.
Claim 20 recites the limitation "the heterocyclic radical alkyl group" on page 12, line 28. There is insufficient antecedent basis for this limitation in the claim. Parent claim 16 recites instead a “heterocyclylalkyl”. Applicant may amend the claim.
Claim 21 recites limitations wherein substituents may be “=N+(O)(R)”, “=N+(O)(OR)”, or “-N+RR’R””, which is indefinite as it would be unclear to one of ordinary skill in the art which compounds are encompassed by this definition. Applicant may amend the claim to remove the cited substituents.
Allowable Subject Matter
Claims 1-25 are free of the prior art.
The closest prior art is from Qian in WO 2011/085641 A1, which teaches bufalin derivatives and methods of treatment of cancer using said derivatives. Of note is compound I-e,
PNG
media_image4.png
359
478
media_image4.png
Greyscale
, see page 19, which is nearly embraced by formula (IV) of instant claim 16. The difference lies in the missing alkylphosphoryl group in reference compound I-e, which is outlined in this image of present formula (IV):
PNG
media_image5.png
298
368
media_image5.png
Greyscale
. Qian teaches that compounds of the reference also include prodrugs (para. [055]), and discusses examples such as esters and amides as carboxylic acid derivatives. See paragraphs [065] and [066]. While phosphates are commonly known in the art as useful prodrug moieties, which would align with the suggestion from Qian to modify comparable Formula III,
PNG
media_image6.png
251
268
media_image6.png
Greyscale
, with a -P(=O)(OR7)(OR8) group (see top of page 3), there is no motivation to modify compound I-e with an alkylphosphoryl group, which would be necessary to arrive at the instantly claimed compounds of Formula (IV). Moreover, there is no suggestion to modify prior art compound I-e specifically at the piperazine ring with said functionality. Therefore, the instant claims are free of the prior art.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jalisa H. Ferguson whose telephone number is (703)756-1489. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/J.H.F./Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626